Please ensure Javascript is enabled for purposes of website accessibility

Why Horizon Pharma PLC Stock Is Spiking Today

By George Budwell – Nov 8, 2018 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Horizon's shares got a boost from the company's outstanding third-quarter earnings report yesterday.

What happened

Shares of the orphan-drug maker Horizon Pharma (HZNP -0.84%) gained 15.9% on Wednesday on nearly five times the normal daily volume. What caused investors to pile into this mid-cap biopharma stock?

Horizon's stock perked up yesterday thanks to an exceptionally strong third-quarter earnings report. The key highlight was Horizon's surging top line during the three-month period.

According to Horizon's press release, its third-quarter sales came in at $325.3 million, handily beating Wall Street's consensus estimate by $13.5 million, according to FactSet consensus. Horizon attributed its outstanding quarter to rising sales for both its primary care portfolio of medicines, as well as the chronic gout treatment Krystexxa. 

A man shouting in excitement at an open laptop computer.

Image Source: Getty Images.

So what

Horizon's shares have been slowly edging higher over the back half of 2018. Even so, the drugmaker's stock was still trading well below average valuation levels for a company of its size and operational capacity prior to yesterday's breakout. After Wednesday's double-digit surge, though, Horizon's price-to-sales ratio rose to 3.49, which is right about the norm for a mid-cap biopharma stock. 

Now what

Can Horizon's stock keep churning higher? Although Horizon's current portfolio of primary care medicines and orphan drug products are exceeding expectations, Wall Street's near-term focus is likely to revolve around the upcoming late-stage data readout for the drugmaker's thyroid eye disease treatment teprotumumab.

Teprotumumab's pivotal stage study fully enrolled in early September, setting the stage for a top-line data readout during the second quarter of next year. This experimental drug is key to Horizon's near-term growth prospects because it is projected to generate peak sales of $250 million, if approved, in the United States alone. Without a positive readout for teprotumumab, Horizon's shares may struggle due to the company's heavy debt load and concerns about the commercial longevity of some of its most valuable primary care brands.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
HZNP
$62.44 (-0.84%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.